France's NicOx announced positive results from a 118 patient blood pressure trial, which compared its experimental arthritis drug naproxcinod and a traditional painkiller, naproxen, in osteoarthritis patients with controlled hypertension. Naproxcinod is the first investigational drug in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donator (CINOD) class of anti-inflammatory agents and part of the trial goal was to evaluate how naproxcinod compared with existing non-steroidal anti-inflammatory agents (NSAIDs), such as naproxen and ibuprofen as these meds can raise blood pressure.
Naproxcinod is nearing the end of a Phase III trial and the company expects to be ready to submit its application to the FDA by mid-209.
- check out the NiCox release [1]
- read the article [2] in Network Medica for more
Related Articles:
NicOx hits high notes in naproxcinod trial [3]
Pfizer cancels NicOx drug trial in Asia [4]
NicOx shares plunge on Pfizer trial failure [5]
Links:
[1] http://www.fiercebiotech.com/press-releases/nicox-announces-favorable-blood-pressure-data-naproxcinod-large-abpm-study-0
[2] http://en.networkmedica.com/noticia/seccion/129/articulo/21415/Frances_NicOx_Reports_Arthritis_Candidate_Naproxcinod_Better_than_Naproxen_for_Patients_with_Hypertension.html
[3] http://www.fiercebiotech.com/story/nicox-hits-high-notes-second-pivotal-trial-naproxcinod/2008-09-15
[4] http://www.fiercebiotech.com/story/pfizer-cancels-nicox-drug-trial-asia/2008-08-25
[5] http://www.fiercebiotech.com/story/nicox-shares-plunge-on-pfizer-trial-failure/2008-05-06